Literature DB >> 17541391

Serum uric acid is associated with microvascular function in hypertensive individuals.

T de A Coutinho1, S T Turner, I J Kullo.   

Abstract

We investigated the relationship of serum uric acid (UA) with resting forearm blood flow (FBF), reactive hyperaemia (RH) and flow-mediated dilation (FMD) of the brachial artery in hypertensive adults (n=506, mean age 62 years, 59% women). UA was measured by a colorimetric method. FBF, RH and FMD were measured by brachial artery ultrasound. Regression analyses were used to assess whether UA was associated with FBF, RH and FMD before and after adjustment for age, sex, systolic BP, diabetes, total and high-density lipoprotein cholesterol, smoking, body mass index (BMI), C-reactive protein (CRP), serum creatinine, alcohol intake, statin and diuretic use and brachial artery diameter (BAD). UA was significantly associated with FBF (P<0.0001) and RH (P=0.0001) but not with FMD (P=0.43). After adjustment for the covariates listed above, higher UA level remained independently associated with a higher FBF (P=0.012) and lower RH (P=0.004). The independent predictors were as follows: (a) higher FBF: lower age, higher BMI, history of smoking, statin use, higher CRP, higher BAD and higher UA levels; (b) lower RH: higher BMI, diabetes and higher UA levels; (c) lower FMD: greater age, male sex, higher BMI, history of smoking, statin use and higher BAD. We conclude that in hypertensive individuals, higher UA levels are associated with higher resting FBF and lower RH, markers of microvascular function, but not with brachial artery FMD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541391     DOI: 10.1038/sj.jhh.1002193

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

1.  Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference.

Authors:  Patrick F McArdle; Brian W Whitcomb; Keith Tanner; Braxton D Mitchell; Alan R Shuldiner; Afshin Parsa
Journal:  BMC Cardiovasc Disord       Date:  2012-03-14       Impact factor: 2.298

2.  A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.

Authors:  Mehmet Kanbay; Bulent Huddam; Alper Azak; Yalcin Solak; Gulay Kocak Kadioglu; Ismail Kirbas; Murat Duranay; Adrian Covic; Richard J Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

3.  Association between Serum Uric Acid and Impaired Endothelial Function: The Circulatory Risk in Communities Study.

Authors:  Jingyun Tang; Keyang Liu; Ehab S Eshak; Renzhe Cui; Ryoto Sakaniwa; Hironori Imano; Jia-Yi Dong; Hiroyasu Iso
Journal:  J Atheroscler Thromb       Date:  2021-12-01       Impact factor: 4.394

4.  Uric acid level and erectile dysfunction in patients with coronary artery disease.

Authors:  Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay
Journal:  J Sex Med       Date:  2013-09-25       Impact factor: 3.802

5.  Could Uric Acid Be Considered a Cardiovascular Risk Factor?

Authors:  Juan-José Rodríguez-Arias; Gabriel Coll-de-Tuero
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-07       Impact factor: 3.738

6.  The relationship of retinal vessel diameters and fractal dimensions with blood pressure and cardiovascular risk factors.

Authors:  Pengli Zhu; Feng Huang; Fan Lin; Qiaowei Li; Yin Yuan; Zhonghai Gao; Falin Chen
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

7.  Sex-Specific Association Between Serum Uric Acid and Retinal Microvessels.

Authors:  Qiaowei Li; Fan Lin; Zhonghai Gao; Feng Huang; Pengli Zhu
Journal:  Med Sci Monit       Date:  2019-12-25

8.  Pharmacotherapy for hyperuricaemia in hypertensive patients.

Authors:  Pedro Henrique França Gois; Edison Regio de Moraes Souza
Journal:  Cochrane Database Syst Rev       Date:  2020-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.